ZINC PYRITHIONE IN COMBINATION THERAPY OF ATOPIC DERMATITIS: PATHOGENETIC SUBSTANTIATION AND RESULTS OF STUDIES
https://doi.org/10.21518/2079-701X-2017-20-171-176
Abstract
The review is devoted to the pathogenetic substantiation of the use of the activated zinc pyrithione agent in atopic dermatitis. The main mechanisms of formation of the pathological process in atopic dermatitis are explained in more details: hereditary predisposition, violations of the barrier function of the skin and immunological dysfunction leading to the development and persistence of chronic inflammation. The role of zinc ions in the pathogenesis of atopic dermatitis is discussed. The article presents the detailed analysis of the main clinical studies of the activated zinc pyrithione agent in atopic dermatitis, its positive effect on such symptoms as itching, skin manifestations, skin microbioma and severity of the disease course.
About the Author
R. S. Fassakhov
Kazan (Volga) Federal University of the Ministry of Education and Science of Russia.
Russian Federation
Russian Federation
MD, Prof.
Kazan
References
1. Клинические рекомендации «Атопический дерматит у детей». Союз педиатров России, Российская ассоциация аллергологов и клинических иммунологов. Российское общество дерматовенерологов и косметологов. 60 c. М., 2016.
2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab, 2015, 66(Suppl 1): 8-16.
3. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol, 1994,30: 35-9.
4. Perkin MR, Strachan DP, Williams HC, Kennedy CT, Golding J, Team AS. Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort study. Pediatr Allergy Immunol, 2004, 15: 221-9.
5. Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg, 2012, 31(3 Suppl): S18-22.
6. Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci, 2013, S0923-1811 (13): 55-8.
7. Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh), 1985, 114: 159.
8. Martel BC, Litman T, Hald A, Norsgaard H, Lovato P, Dyring-Andersen B, et al. Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. Exp Dermatol, 2016, 25: 453-9.
9. Brenninkmeijer EE, Spuls PI, Legierse CM, Lindeboom R, Smitt JH, Bos JD. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol, 2008, 58: 407-14.
10. Esparza-Gordillo J, Weidinger S, Folster-Holst R, Bauerfeind A, Ruschendorf F, Patone G, et al. A common variant on chromosome 11q13 is associated wit atopic dermatitis. Nat Genet, 2009, 41: 596-601.
11. Paternoster L, Standl M, Chen CM, Ramasamy A, Bønnelykke K, Duijts L, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet, 2011, 44: 187-92.
12. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet, 2012, 44: 1222-6.
13. Kabashima-Kubo R, Nakamura M, Sakabe J, Sugita K, Hino R, Mori T, et al. A group of atopic dermatitis without IgE elevation or barrier impairmentshows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci, 2012, 67: 37-43.
14. Weidinger S, Rodríguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, et al. Filaggrinmutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol, 2007, 127: 724-726.
15. Mori T, Ishida K, Mukumoto S, Yamada Y, Imokawa G, Kabashima K, et al. Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis. Br J Dermatol, 2010, 162: 83-90.
16. Van Smeden J, Bouwstra JA. Stratum Corneum Lipids: Their Role for the Skin Barrier Function in Healthy Subjects and Atopic Dermatitis Patients. Curr Probl Dermatol, 2016; 49: 8–26.
17. Cork MJ, Danby SG, Vasilopoulos Y et al. Epider mal Barrier Dysfunction in Atopic Dermatitis. Journal of Investigative Dermatology, 2009, 129: 1892-1908.
18. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J. Invest. Dermatol., 2012, 132: 751–762
19. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol, 2013, 131(2): 280–291.
20. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol, 2014, 134(4): 792–799.
21. Furue M, Chiba T, Tsuji G et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergology International, 2017, 66: 398-403.
22. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol, 2014, 71(1): 116-32.
23. Bewley A. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol, 2008, 158: 917-920.
24. Sokolova A, Smith SD. Factors contributing to poor treatment outcomes in childhood atopic dermatitis. Australas J Dermatol, 2015, 56: 252-257.
25. Charman C, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic dermatitis. Br J Dermatol, 2000, 142: 931–936.
26. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess. 2000, 4: 1–191.
27. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol, 2011, 165: 808-814.
28. Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol, 2015, 27: 499-506.
29. Lansdown AB. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit. Rev. Toxicol., 1995, 25(5): 397-462.
30. Rowlands C.G., Danby F.W. Histopathology of psoriasis treated with zinc pyrithione. Am. J. Dermatopathol., 2000, 22(3): 272–276.
31. Andreini C, Banci L, Bertini I, et al. Counting the zinc-proteins encoded in the human genome. J Proteome Res, 2006, 5: 196-201.
32. Maywald M, Rink L. Zinc homeostasis and immuno senescence. J Trace Elem Med Biol, 2015, 29: 24-30.
33. Takahashi H, Nakazawa M, Takahashi K, et al. Effects of zinc deficient diet on development of atopic dermatitis-like eruptions in DS-Nh mice. J Dermatol Sci, 2008, 50: 31-9.
34. Rink L, Haase H. Zinc homeostasis and immunity. Trends Immunol, 2007, 28: 1-4.
35. Kim JE, Yoo SR, Jeong MG, et al. Hair zinc levels and the efficacy of oral zinc supplementation in patients with atopic dermatitis. Acta Derm Venereol, 2014, 94: 558-62.
36. Казначеева Л.Ф., Молокова A.B., Казначеев К.С. и др. Патогенетическое обоснование наружной терапии атопического дерматита у детей. Российский аллергологический журнал, 2004, 2: 95-98.
37. Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Современная наружная терапия хронических воспалительных заболеваний кожи у детей (опыт клинического применения препарата Скин-кап) Педиатрия, 2008, 87(4): 90-95.
38. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Пиритион цинка (Скин-кап) в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский аллергологический журнал, 2007, 2: 75-81.
39. Hepburn L, Hijnen DJ, Sellman BR et al. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. Br J Dermatol, 2017 Jul, 177(1): 63-71.
40. Arora S K, Dewan P, Gupta P. Microbiome: Paediatricians’ perspective. Indian J Med Res, 2015, 142(5): 15–24.
41. Salava A, Lauerma A. Role of the skin microbiome in atopic dermatitis. Clin Transl Allergy, 2014, 4: 33.
42. Коростовцев Д.С., Пампура А.Н., Фассахов Р.С., Сукманская Е.О., Петровский Ф.И. Клиническая эффективность и антимикробная активность пиритиона цинка при атопическом дерматите у детей. Педиатрическая фармакология, 2009, 6(1): 64-69.
43. Мокроносова М.А., Максимова А.Е., Батуро А.П., Кашаева О.В. Влияние различных методов наружной терапии на колонизацию кожи St. aureus и течение атопического дерматита. Российский аллергологический журнал, 2004, 1: 58-61.
44. Маланичева Т.Г., Саломыков Д.В., Глушко Н.И. Диагностика и лечение атопического дерматита у детей, осложненного микотической инфекцией. Российский аллергологический журнал, 2004, 2: 90-93.
45. Nenoff P, Haustein UF. Effect of anti_seborrhea substances against Pityrosporum ovale in vitro. Hautarzt., 1994, 45(7): 464-467.
46. Мокроносова М.А., Пыж В.В., Кашаева О.В. и др. Терапевтический эффект активированного цинка пиритиона у больных с синдромом атопического дерматита/экземы с сенсибилизацией к дрожжеподобным грибам. Россий ский аллергологический журнал, 2004, 3: 83–87.
47. Маланичева Т.Г., Саломыков Д.В., Глушко Н.И. Клинико-иммунологическая характеристика и особенности местной терапии атопического дерматита у детей при сочетанном поражении кожи и слизистой оболочки желудка и двенадцатиперстной кишки грибами рода Candida. Аллергология, 2006, 4: 14–19.
48. Мокроносова М.А., Максимова А.Е., Батуро А.П. и др. Влияние различных методов наружной терапии на колонизацию кожи Staphylococcus aureus и течение атопического дерматита. Россий ский аллергологический журнал, 2004, 1: 58-61.
49. Короткий Н.Г., Намазова-Баранова Л.С., Новик Г.А. и др. Уверенность родителей в эффективности и безопасности лечения атопического дерматита у детей. Сравнение активированного пиритиона цинк с другими вариантами наружной терапии в рамках ступенчатого подхода. Педиатрическая фармакология, 2009, 6 (3): 67-71.
Review
For citations:
Fassakhov RS. ZINC PYRITHIONE IN COMBINATION THERAPY OF ATOPIC DERMATITIS: PATHOGENETIC SUBSTANTIATION AND RESULTS OF STUDIES. Meditsinskiy sovet = Medical Council. 2017;(20):171-176. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-171-176
Views:
1150
Email this article 